Related Experiment Video
Updated: Jun 2, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
A case of acquired Fanconi syndrome induced by zoledronic acid
Tetsuhiro Yoshinami1, Toshinari Yagi, Daisuke Sakai
1Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan. yosinami-te@mc.pref.osaka.jp
Abstract:
A 61-year-old woman with metastatic breast cancer was diagnosed as having acquired Fanconi syndrome. In this case, the cause of this syndrome was most likely zoledronic acid (Zometa), which had been infused intravenously at a dose of 4 mg over 15 minutes weekly because of malignancy-associated hypercalcemia. Zoledronic acid is nephrotoxic and may induce severe tubular dysfunction, which can cause development of Fanconi syndrome. Therefore, close monitoring of proximal tubular function is recommended during therapy with zoledronic acid, especially when frequent administration of zoledronic acid is needed.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease I: Introduction
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
